Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, EMMAUS LIFE SCIENCES, INC. reported revenue of $12M, down 25.2% year over year. Operating margin was 1.9% and net margin -60.2%, on a free-cash-flow margin of -0.1% with capital expenditure at 0.0% of revenue. Every figure is computed directly from EMMA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $12M | 1.9% | -60.2% |
| FY2024 | $17M | -11.4% | -38.7% |
| FY2023 | $30M | 12.0% | -12.6% |
| FY2022 | $18M | -35.8% | -57.8% |
| FY2021 | $21M | -29.7% | -77.4% |
How does EMMA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.